Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REJOICE-Ovarian03
NCT07791732Phase 3Not yet recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Jul 2029
01
Overview
A Phase 3 trial of raludotatug deruxtecan in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Daiichi Sankyo Co., Ltd.. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
raludotatug deruxtecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT07791732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791732.